Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

Ceribelli, Angela; Motta, Francesca; Santis, Maria De; Ansari, Aftab A.; Ridgway, William M.; Gershwin, M. Eric; Selmi, Carlo

doi:10.1016/j.jaut.2020.102442

Cited by 113 publications

(107 citation statements)

References 21 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence, the screening of the patients, particularly those receiving nbDMARDs and bDMARDs, for such common infections is a part of a routine in pediatric rheumatology practice. Novel coronavirus demonstrating high morbidity and mortality worldwide has raised substantial concern for the patients with immune-related conditions and subspecialties as rheumatology dealing with their management [24,25]. In our cohort, 14.3% of the patients interrupted their medications during the pandemic period.…”

Section: Discussionmentioning

confidence: 91%

“…These results underline the importance of patient-doctor communication throughout the patient's entire treatment process. Current evidence suggests not withdrawing the immunosuppressive treatment and no need for additional dose adjustment during the pandemic process unless physician indication or presence of speci c symptoms [7,8,15,[24][25][26]. Although current guidelines, yet available online, relevant to the topic are mostly based on adult series, they served as an essential guide to elucidate multiple issues yet not resolved in this eld [9,27,28].…”

Section: Discussionmentioning

confidence: 99%

“…Another link between the eld of rheumatology and the current pandemic is the shared drugs commonly used in rheumatology and recently included in the management of COVID-19 [25,32]. Novel researches, presenting a better understanding of the immune mechanisms with cytokine networks in the process of SARS-CoV-2, started to illuminate the etiopathogenetic patterns as well as the treatment [4,16,33].…”

Section: Discussionmentioning

confidence: 99%

“…Glucocorticoids and IVIG, which are used in many elds of medicine and are frequently used in rheumatology, are the rst remedies for COVID-19, but have failed to take part in routine use [6,25]. The fact that glucocorticoids may increase virus replication on one hand, and have potent anti-in ammatory effects, on the other hand, led to a contradiction in pandemic and this controversy extends to the management of chronic patients already under glucocorticoid therapy [25,36]. When we go back over our data, there were no active usages of steroid or IVIG among the contacted patients.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

The impact of COVID-19 pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

Köker

Demirkan

Kayaalp

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: The aim of the research was to further broaden current knowledge of whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) entails a risk for children with rheumatic diseases regarding immunosuppressive treatment.Methods: Telephone-survey was administered by conducting interviews with the parents. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments.Results: Patients who were followed up with immunosuppressive treatment (n=439) were attempted to be contacted between 1 May 2020 and 15 May 2020. The diagnostic distribution of patients who were accessible and eligible for the study was as follows; juvenile idiopathic arthritis (JIA) (n=243, 58.7%), autoinflammatory diseases (n=109, 26.3%), autoimmune connective tissue diseases (n=51, 12.3%) and vasculitis (n=11, 2.7%). In the entire cohort, the mean age was 12 ± 4.7 years, and 54.1% (n=224) of the patients were female. One patient with seronegative polyarticular JIA, previously prescribed methotrexate and receiving leflunomide during pandemic has been identified to be diagnosed with COVID-19. None of the patients, including the patient diagnosed with COVID-19, had any severe symptoms. More than half of the patients with household contacts required hospitalization as they were asymptomatic.Conclusion: Although circumstances such as compliance in social distancing policy, transmission patterns, attitude following contact may influence the results, immunosuppressive treatment does not seem to pose additional risk in terms of COVID-19.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The impact of COVID-19 pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

Köker

Demirkan

Kayaalp

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…For now, the experience with such agents largely consists of anecdotal case reports and small clinical trials. 10 As of this writing, more than 270 clinical trials of various therapeutics for COVID-19 are registered at clinincaltrials.gov (clinicaltrials.gov). A number of agents have been proposed or are in use, including anti-IL-1, anti-GM-CSF, anti-TNF, and Janus kinase inhibitors.…”

mentioning

confidence: 99%

Cytokine storm and the prospects for immunotherapy with COVID-19

Calabrese

2020

CCJM

View full text Add to dashboard Cite

The statements and opinions expressed in COVID-19 Curbside Consults are based on experience and the available literature as of the date posted. While we try to regularly update this content, any offered recommendations cannot be substituted for the clinical judgment of clinicians caring for individual patients. ABSTRACT Knowledge about the pathobiology of SARS-COV-2 as it interacts with immune defenses is limited. SARS-COV-2 is spread by droplets that come into contact with mucous membranes. COVID-19 is characterized by 3 stages: asymptomatic-paucisymptomatic incubation, nonsevere symptomatic illness for 80% of those infected, and severe respiratory illness. A syndrome characterized by hypercytokinemic infl ammation referred to as a "cytokine storm" can occur in patients with advanced disease. Effective antiviral agents that can prevent viral infection in exposed individuals are needed.

show abstract

Emerging Trends and Future Prospects in Microfluidic Systems for Prevention and Diagnosis of Infection Pathogens

Dabbagh Moghaddam,

Rafiee,

Setayeshfar

et al. 2024

Adv Materials Technologies

View full text Add to dashboard Cite

Infectious diseases caused by bacteria, viruses, fungi, and parasites pose a significant societal challenge. In response, scientists are developing advanced technology to enhance the prevention, diagnosis, and treatment of such diseases. One such promising technology is microfluidic systems, which are utilized in organ‐on‐a‐chip systems to replicate the microenvironments of organs. These systems have potential applications in drug screening, disease modeling, and personalized medicine. This review provides an overview of recent advances in organ‐on‐a‐chip platforms and their potential for preventing and diagnosing various infections. After discussing traditional techniques employed in studying infectious diseases, the role of microfluidic platforms in detecting infections is delved in. It is expound on advanced microfluidic‐based strategies for infection diagnosis, such as the polymerase chain reaction‐based microfluidic devices, enzyme linked immunosorbent assay‐based microfluidic devices, hierarchical nanofluidic molecular enrichment systemand µWestern blotting‐based microfluidic devices, and smartphone‐based microfluidic devices. Additionally, future research challenges and perspectives are discussed on microfluidic systems in biomedical and regenerative medicine applications. Consequently, microfluidic platforms have the potential to serve as fundamental frameworks for understanding infectious diseases, thereby leading to personalized regenerative medicine. hierarchical nanofluidic molecular enrichment system

show abstract

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

Cited by 113 publications

References 21 publications

The impact of COVID-19 pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

The impact of COVID-19 pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

Cytokine storm and the prospects for immunotherapy with COVID-19

Emerging Trends and Future Prospects in Microfluidic Systems for Prevention and Diagnosis of Infection Pathogens

Contact Info

Product

Resources

About